Company Profile: Spineart

Background

Spineart is a privately held medical device company dedicated to simplifying spinal surgery through the design, development, and promotion of safe and efficient solutions for spine surgeons, operating room teams, and patients. Established in 2005, the company has introduced unique technologies in minimally invasive surgery, motion preservation, fusion, biologics, and fracture treatment. Operating in over 60 markets worldwide, Spineart combines traceable barcoded sterile-packed implants with compact instrument sets, promoting greater safety, cost-efficiency, and compliance in hospitals.

Key Strategic Focus

Spineart's strategic focus centers on:

Innovation in Spinal Surgery: Developing cutting-edge technologies to enhance surgical outcomes.

Global Expansion: Strengthening its presence in existing markets and entering new ones, particularly in the United States.

Technological Integration: Incorporating advanced technologies such as 3D printing, digital surgical planning, navigation, and robotics into its product offerings.

Education and Collaboration: Establishing centers like the Spineart Innovation Center in Dallas to foster learning and collaboration among spine surgeons, hospitals, and academic institutions.

Financials and Funding

Spineart has secured significant funding to support its growth and innovation initiatives:

August 2024: Raised over CHF 20 million in convertible financing, with more than CHF 15 million contributed by existing shareholders and employees. The funds are allocated for investments in enabling technologies, follow-up of BAGUERA® C IDE studies, completion of a new 43,000 sq ft factory near Geneva, and the opening of the Spineart Innovation Center in Dallas.

April 2024: Invested €10 million in SpinEM Robotics, a deep tech startup specializing in navigation solutions for robotic spinal surgery, marking the beginning of a development collaboration to revolutionize spinal surgery.

2016: Secured a €30 million investment from Gimv to reinforce sales, expand geographically, and develop innovative products.

Pipeline Development

Spineart's key pipeline developments include:

BAGUERA® C Cervical Disc Prosthesis: Designed to maintain or restore segmental motion and disc height in the cervical spine. Interim analyses of 1-level and 2-level Investigational Device Exemption (IDE) studies met the threshold for non-inferiority. The company plans to submit a Premarket Approval (PMA) to the U.S. FDA by the end of August 2025.

Technological Platform and Innovation

Spineart distinguishes itself through several proprietary technologies and innovative methodologies:

Ti-LIFE Technology: A proprietary additive manufacturing process that creates a porous structure closely mimicking trabecular bone, promoting osseous in-growth and cell colonization. Over 100,000 Ti-LIFE cages have been sold worldwide.

PERLA® App: Developed in collaboration with eCential Robotics, this application integrates Spineart's PERLA® TL screw systems with the eCential Robotics Op.n™ platform, enhancing surgical precision and workflow efficiency. The app received 510(k) clearance from the U.S. FDA in March 2025.

Leadership Team

Jerome Trividic: Chief Executive Officer. Joined Spineart in 2011, previously served as Chief Strategy Officer and President for the U.S. Holds a Master's degree and an Engineering degree from Ecole Polytechnique, Paris.

Laurent Nodé-Langlois: Chief Technology Officer. Appointed in June 2024, with over 25 years of experience in biomechanics, surgical navigation, innovation, and intellectual property. Former Managing Director at General Electric, advancing GE Healthcare's 3D imaging and navigation technologies.

Guillaume Amblard: Chief Product Officer. Joined Spineart in 2008, leading R&D and Product Marketing. Holds a degree in Engineering from Ecole Nationale des Arts et Métiers.

Leadership Changes

June 2024: Appointment of Laurent Nodé-Langlois as Chief Technology Officer to lead the Enabling Technologies business unit, focusing on digital surgical planning, navigation, and robotics.

Competitor Profile

Market Insights and Dynamics

The global spinal surgery market is characterized by:

Market Size and Growth: A rapidly growing sector driven by an aging population, increasing prevalence of spinal disorders, and advancements in surgical technologies.

Industry Trends: Emphasis on minimally invasive procedures, adoption of robotic-assisted surgeries, and development of patient-specific implants.

Competitor Analysis

Key competitors in the spinal surgery market include:

Medtronic: Offers a comprehensive range of spinal implants and surgical navigation systems.

Stryker: Provides spinal implants, biologics, and surgical navigation technologies.

Zimmer Biomet: Specializes in spinal fusion products and minimally invasive surgical solutions.

NuVasive: Focuses on minimally invasive surgical products and procedures for spine surgery.

Strategic Collaborations and Partnerships

Spineart has engaged in significant collaborations to enhance its market position and innovation capacity:

eCential Robotics: Partnered to develop the PERLA® App, integrating Spineart's screw systems with eCential's robotic navigation platform.

SpinEM Robotics: Invested €10 million in April 2024 to collaborate on advanced navigation and robotic assistance technologies for spinal surgery.

Solco Biomedical: Entered a distribution agreement in September 2023, appointing Solco as the exclusive distributor of BAGUERA® C in the Republic of Korea.

Operational Insights

Spineart's strategic considerations include:

Manufacturing Expansion: Construction of a new 43,000 sq ft factory near Geneva to consolidate manufacturing and logistics activities, equipped with state-of-the-art additive manufacturing and CNC machines.

Innovation Centers: Opening of the Spineart Innovation Center in Dallas to provide spine surgeons with access to next-generation navigation and robotics technologies.